Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8 billion in 2014, and the intellectual property (IP) rights to Esbriet (pirfenidone) in the US to Legacy Pharma Inc. SEZC. Financial terms were undisclosed.
Financials
Esbriet, an idiopathic pulmonary fibrosis (IPF) drug, saw peak sales of CHF 1.14 billion in 2021 but dropped to USD 54 million in 2024 due to generic competition. The divestiture follows Roche’s strategic shift to focus on innovative therapies.
Drug Profile
Esbriet, developed by InterMune, was Roche’s key IPF treatment. Generic erosion and declining sales prompted the transfer to Legacy Pharma, which plans to maintain US market access.
Strategic Outlook
The deal allows Roche to streamline operations amid patent expiries. Legacy Pharma gains a foothold in IPF with Esbriet, while Roche retains global rights outside the US.-Fineline Info & Tech
